Triam Zubeldia
About Triam Zubeldia
Triam Zubeldia is an Associate at Carta, specializing in financial research and analysis for B2B platforms in various sectors. He has a diverse background in technology investment banking, research, and entrepreneurship, having held positions at ScaleBridge Capital, Kniterate, and Universitat de Barcelona.
Work at Carta
Triam Zubeldia has been employed at Carta as an Associate since 2022. In this role, Zubeldia focuses on financial research and analysis, particularly for B2B platforms in the Industrials, Biotech, and Climate sectors. Zubeldia has successfully delivered over 200 EMI and CSOP valuations to clients, showcasing expertise in financial valuation and analysis.
Previous Experience at ScaleBridge Capital
Before joining Carta, Zubeldia worked at ScaleBridge Capital in Technology Investment Banking for a period of seven months in 2021. This role was based in London, England, and involved providing financial advisory services within the technology sector.
Co-Founder and COO at Kniterate
Zubeldia co-founded Kniterate and served as COO from 2015 to 2019. During this time, Zubeldia contributed to the development of a company focused on innovative textile technology. Zubeldia later took on the role of Co-CEO at Kniterate from 2019 to 2020, further shaping the company's strategic direction.
Education and Expertise
Zubeldia holds a Bachelor of Science degree in Banking and Finance from the University of London. Additionally, Zubeldia studied Biotechnology and Agricultural Biology at Universitat de Barcelona, achieving both BS and MS degrees. Zubeldia has passed Level 2 of the CFA program, indicating a strong foundation in financial analysis and investment principles.
Research Background
Zubeldia has a background in research, having worked as an Associate Researcher at Universitat de Barcelona from 2007 to 2010. Zubeldia also served as a Visiting Researcher at UCL for six months in 2010. This experience includes a foundation in plant molecular biology, which complements Zubeldia's expertise in the biotech sector.